The biotech sector has been sliding, but a turnaround could be afoot. Chad Morganlander of Stifel Nicolaus and Craig Johnson of Piper Jaffray discuss with Brian Sullivan. » Read More
BlackRock vice chairman and global chief investment officer of equities Bob Doll says it's time to re-introduce risk into portfolios.
The week ended with a stunningly bad November jobs report, indicating that the economy is getting much worse much faster than expected, and suggesting that the recession will be especially deep and prolonged. It was a grim end to a volatile week, beginning with a huge loss on Monday, but CNBC guests continued to encourage investors to buy stocks, saying now is the time to position oneself for the recovery and take advantage of valuations.
The stock market was far off its morning lows, coming close to turning positive, as investors shook off a handful of weak economic reports and snapped up biotech shares and other defensive plays.
Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.
The Thanksgiving-week rally took the markets up 10 percent, and with a 28-percent gain, financials outperformed just about everything else. BlackRock's Bob Doll sees investors cashing in on those gains this week, and recommends a move to more defensive stocks.
One of the weapons widely used to fight cholesterol might be more powerful than previously believed. Is there a trade here?
While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.
In this Web Extra find out why investors who are attempting to battle the bear with biotech are keeping a close eye on Amgen..
Stocks clawed back from five-year lows on Thursday, led by a bounce in energy and health-care stocks...
Stocks made a third attempt at a rally Thurdsay though techs took a beating amid worries about the outlook for the sector.
A rally spurred by bargain hunting fizzled Thursday as weakness in technology leaders offset strength energy-related companies.
Stocks wavered after an early pop Thursday as the latest batch of earnings and a disappointing weekly jobless report stoked recession fears.
U.S. stocks opened slightly higher despite worse-than-expected weekly jobless numbers and growing recession fears.
The Dow made another triple digit move on Monday this time soaring more than 400 points higher.
Despite a slowing economy, drug stocks such as Abbott Labs and Genentech posted positive earnings reports. Is health care the best defensive play in this market?
Following are the “Fast & Furious” trades - hot ways to play next week's market moving events.
As the Dow, S&P and NASDAQ chalk up some of the biggest weekly losses ever, how does that translate to dollar terms?
Even in the worst of times, don't give up on stocks.
This morning the world's biggest biotech company released the highly-anticipated detailed test results on its crucial, late-stage experimental osteoporosis drug known as D-mab. And they look good.